Theoretically, this is also true of novel therapeutic options for anemia of chronic disease (ACD) or AOC, especially the ones that target the hepcidin-ferroportin (FPN)-1 axis or HIF activation. The gene discussed is HAMP; the disease is anemia (phenotype).